Compared with the treatment of romidepsin or anti-PD-1 antibodies alone, the combination of the two drugs not only downregulates the immunosuppression of romidepsin but also increases the tumor killing effect of anti-PD-1 immunotherapy, ultimately achieving the optimal anti-tumor effect. Here, PDCD1 is linked to neoplasm.